Experimental combo therapy targets Hard-to-Treat lymphoma
NCT ID NCT05801913
First seen Mar 08, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This early-phase study tests whether giving specially engineered immune cells (CAR T cells) along with a vaccine can safely treat people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T cells are designed to recognize and attack cancer cells, while the vaccine may help the immune system fight the cancer longer. About 15 participants will receive this combination after chemotherapy to see if it is safe and feasible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.